Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Cullinan Therapeutics (CGEM) Shares Outstanding (Weighted Average) (2020 - 2023)

Cullinan Therapeutics (CGEM) has 4 years of Shares Outstanding (Weighted Average) data on record, last reported at $42.7 million in Q3 2023.

  • For Q3 2023, Shares Outstanding (Weighted Average) fell 4.96% year-over-year to $42.7 million; the TTM value through Sep 2023 reached $42.7 million, down 4.96%, while the annual FY2022 figure was $45.2 million, 4.84% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $42.7 million in Q3 2023 per CGEM's latest filing, up from $40.0 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $45.2 million in Q4 2022 and bottomed at $18.7 million in Q1 2020.
  • Average Shares Outstanding (Weighted Average) over 4 years is $36.8 million, with a median of $42.7 million recorded in 2021.
  • Peak YoY movement for Shares Outstanding (Weighted Average): surged 123.91% in 2021, then fell 10.53% in 2023.
  • A 4-year view of Shares Outstanding (Weighted Average) shows it stood at $19.9 million in 2020, then soared by 116.61% to $43.1 million in 2021, then rose by 4.84% to $45.2 million in 2022, then decreased by 5.38% to $42.7 million in 2023.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Weighted Average) were $42.7 million in Q3 2023, $40.0 million in Q2 2023, and $40.7 million in Q1 2023.